1995; Porgador and Gilboa 1995; Boczkowski, Nair et al. 1996). DCs mixed in vivo with irradiated tumor cells have been shown to produce a protective immune response against a challenge with autologous tumor cells (Coveney, Wheatley et al. 1997). Tumor-specific CTL response was also detectable. Clinically, infusion of DCs has shown evidence of antitumor activity in patients with solid tumors (Hirschowitz, Foody et al. 2004; Ribas 2005; Small, Sacks et al. 2007). These attr ibutes make DCs a pivotal component in therapeutic strategies of many curr ent immune-based therapies in cancer. Immune Function Capacity in Ovarian Cancer Patients 1.3 The majority of women diagnosed with canc er of the ovary present in advanced stage (Jemal, Siegel et al. 2009) with 5-y ear survival rates of 46.7% for Stage IIIa, 41.5% for Stage IIIb, and 32.5% for Sta ge IIIc (Heintz, Odicino et al. 2006). Despite a gradual improvement in over all survival over the past decade, approximately 75% of the wo men with Stage III/IV ovarian cancer who achieve a complete clinical response will relapse, as will 50% of those achieving pathologic complete response at a median time of 16-24 months depending on risk factors (Gadducci, Sartori et al. 1998; Markman, Liu et al.